New letters urge the Centers for Medicare & Medicaid Services to expand Medicare and Medicaid to include FDA-approved ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...
New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...
A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, ...
The conversation surrounding health care reform has intensified in recent years, revealing deep divides in how we view personal responsibility, government intervention and public health ...
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...
Will Medicare end Novo Nordisk's obesity drug boom? It's not surprising that CMS chose Ozempic, Wegovy, and Rybelsus for Medicare drug price negotiations. Between November 2023 and October 2024 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback